Drugmakers must sell established time-release drug when mergers overlap, Hoffman says
When two merging drugmakers both make certain time-released “complex” drugs, the US Federal Trade Commission believes the established drug, and not the drug in the research and development pipeline, must be divested, the acting director of the FTC’s bureau of competition has said.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.